Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 215-662-8 | CAS number: 1338-24-5
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Developmental toxicity / teratogenicity
Administrative data
- Endpoint:
- developmental toxicity
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Study period:
- 2018-02-20 to 2018-03-22
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 2 018
Materials and methods
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- OECD Guideline 414 (Prenatal Developmental Toxicity Study)
- Version / remarks:
- Adopted 22 January 2001
- Deviations:
- no
- GLP compliance:
- yes
- Limit test:
- no
Test material
- Reference substance name:
- Naphthenic acids
- EC Number:
- 215-662-8
- EC Name:
- Naphthenic acids
- Cas Number:
- 1338-24-5
- Molecular formula:
- For the acidic (naphthenic) fraction: CnH2n+zO2, where n = carbon number and z = homologous group series number: z = 0 when no ring structures are present, z = -2 when 1 ring is present, z = -4 when 2 rings are present etc. For the non-acidic fraction: not applicable
- IUPAC Name:
- 11-(decahydronaphthalen-2-yl)undecanoic acid; 11-cyclopentylundecanoic acid; 15-cyclohexylpentadecanoic acid; 3-(tetradecahydroanthracen-2-yl)propanoic acid; 4-(tetradecahydroanthracen-2-yl)butanoic acid; 7-(tetradecahydroanthracen-2-yl)heptanoic acid; 9-(octahydropentalen-2-yl)nonanoic acid; dodecahydro-1H-phenalene-1-carboxylic acid
- Test material form:
- liquid
Constituent 1
- Specific details on test material used for the study:
- SOURCE OF TEST MATERIAL
- Source and lot/batch No.of test material: 2017787NA12
- Expiration date of the lot/batch: 31July2019
- Purity: Considered as 100%
STABILITY AND STORAGE CONDITIONS OF TEST MATERIAL
- Storage condition of test material: Room temperature (15-25 °C, ≥ 70 Relative Humidity%)
- Solubility and stability of the test substance in the solvent/vehicle: test item formulation samples in the 10-220 mg/mL concentration range (using 1,2-propylene-glycol as vehicle) were proven to be stable for at least 15 days when stored at room temperature (20±5°C).
TREATMENT OF TEST MATERIAL PRIOR TO TESTING
- Treatment of test material prior to testing: The test item was formulated in the vehicle (1,2-propylene-glycol) at the appropriate concentrations according to the dose level and volume selected.
OTHER SPECIFICS: No correction for purity of the test item was applied.
Test animals
- Species:
- rat
- Strain:
- Wistar
- Remarks:
- Hannover
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Charles River Laboratories, Research Models and Services, Germany GmbH (Sandhofer Weg 7, D-97633 Sulzfeld, Germany) from SPF colony.
- Age: 13 weeks old at mating
- Weight at study initiation: 181-242 g
- Fasting period before study: No
- Housing: Standard laboratory conditions; individual housing.
Bedding: Lignocel® Hygienic Animal Bedding produced by J. Rettenmaier & Söhne GmbH+Co.KG (Holzmühle 1, D-73494 Rosenberg, Germany were used in the study (Batch number: 03018171025, Expiry date: 25 October 2020).
Nesting: Arbocel crinklets natural nesting material produced by J. Rettenmaier & Söhne GmbH+Co.KG (Holzmühle 1, D-73494 Rosenberg, Germany) was used in the study (Batch number: 05072170426, Expiry date: 19 April 2020).
- Diet and water (e.g. ad libitum): The animals were provided with ssniff® SM Autoclavable Complete Diet for Rats/Mice – Breeding and Maintenance (Ssniff Spezialdiäten GmbH, D-59494 Soest, Germany) and tap water (in water bottles) as for human consumption, ad libitum.
- Acclimation period: 19 days
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 19.8-24.5°C (target: 22 ± 3°C)
- Humidity (%): 31-59% (target: 30-70%)
- Air changes (per hr): 15-20 air exchanges/hour
- Photoperiod (hrs dark / hrs light): 12 hours daily, from 6.00 a.m. to 6.00 p.m.
IN-LIFE DATES: From 20 February 2018 to 22 March 2018
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- propylene glycol
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS:
- The test item was formulated in the vehicle (1,2-propylene-glycol) at the appropriate concentrations according to the dose level and volume selected.
- Formulations were prepared prior to administration to the animals at the appropriate frequency (not more than 6 days before use).
VEHICLE
- Justification for use and choice of vehicle (if other than water): Based on the dose range finding study, 1,2-propylene-glycol was selected as a suitable vehicle for this study.
- Concentration in vehicle: 10-220 mg/mL concentration range
- Concentration in vehicle: 0, 13.3, 40 and 120 mg/mL
- Treatment volume: 5 mL/kg body weight
- Expiry date: 31 May 2022 - Analytical verification of doses or concentrations:
- yes
- Details on analytical verification of doses or concentrations:
- Analysis of test item formulations for concentration and/or homogeneity was performed two times during the treatment period using a validated GC-FID (Gas Chromatography - Flame Ionization Detection) method. Top, middle and bottom samples were taken from the test item formulations during the first week and on the last week of treatment. Samples were taken in duplicate (1 mL/each), one set to analyse and one set as a back-up, if required for any confirmatory analyses. Similarly, duplicate samples were taken from the middle of the vehicle control formulation for concentration measurement.
Acceptance criterion of the concentration analysis was set according to the analytical method validation, expected to be at 100 ± 15% of the nominal concentration.
Acceptance criteria of the homogeneity was that the CV of replicates (top, middle and bottom of test item formulations) to be less than 10%.
Any samples not required for analysis were discarded following acceptance of the results of the formulation analysis by the Principal Investigator and Study Director. - Details on mating procedure:
- The oestrus cycle of female animals was examined shortly before start of pairing. After acclimation, the females were paired according to their oestrus cycle with males in the morning for approximately 2-3 hours (1 male : 1 female) until at least 24 sperm positive females/group were attained. After the daily mating period, a vaginal smear was prepared and stained with 1% aqueous methylene blue solution. The smear was examined with a light microscope; the presence of a vaginal plug or sperm in the vaginal smear was considered as evidence of copulation (gestation day 0, GD 0). Sperm positive females were separated and caged individually.
- Duration of treatment / exposure:
- 14 days
- Frequency of treatment:
- Daily
- Duration of test:
- 31 days
Doses / concentrationsopen allclose all
- Dose / conc.:
- 0 mg/kg bw/day (nominal)
- Remarks:
- Control
- Dose / conc.:
- 66.7 mg/kg bw/day (nominal)
- Remarks:
- Low dose
- Dose / conc.:
- 200 mg/kg bw/day (nominal)
- Remarks:
- Mid dose
- Dose / conc.:
- 600 mg/kg bw/day (nominal)
- Remarks:
- High dose
- No. of animals per sex per dose:
- 24
- Control animals:
- yes, concurrent vehicle
- Details on study design:
- - Dose selection rationale: The doses were selected based on available information from a dose range finding study in pregnant Hannover Wistar rats. In this study, no signs of systemic toxicity were observed up to and including the 300 mg/kg bw/day dose level. Reduced food consumption (up to 50% below control), body weight (up to 13.3% below control), decreased body weight gain (55% below control for the treatment period) was observed in the High dose (1000 mg/kg) dams. The High dose was considered to be above the maximum tolerated dose and the 300 mg/kg/day dose level was well tolerated; hence it was estimated that a suitable High dose for the main study was 600 mg/kg/day. Based on this information, the doses of 66.7, 200 and 600 mg/kg bw/day were deemed suitable for the purpose of the study. The oral route was selected since it is a route of administration recommended by the OECD guideline No. 414 and it was considered suitable to provide the exposure required for this developmental toxicology study.
Examinations
- Maternal examinations:
- DETAILED CLINICAL OBSERVATIONS: Yes
- Animals were inspected for signs of morbidity and mortality twice daily (at the beginning and end of each working day).
- Cage-side (general) clinical observations were made twice daily (at the beginning and end of each working day).
- Only one general clinical observation was made on the first day (in the afternoon), on the afternoon on those days when detailed clinical observation was made in the morning.
- Detailed clinical observation was made only once on necropsy days (in the morning).
- The animals were monitored for any changes including pertinent behavioural changes and signs of toxicity including mortality, changes in skin, fur, eyes, mucous membranes, occurrence of secretions and excretions, and autonomic activity (e.g. lachrymation, piloerection, pupil size, unusual respiratory pattern), changes in gait, posture and response to handling as well as the presence of clonic or tonic movements, stereotypies (e.g. excessive grooming, repetitive circling), bizarre behaviour (e.g. self-mutilation, walking backwards), tremors, convulsions, salivation, diarrhoea, lethargy, sleep and coma.
- On GD 13 and/or 14, the sperm positive females were examined for the presence of vaginal bleeding or “placental sign” (intrauterine extravasation of blood as an early sign of pregnancy in rat, which is considered to confirm implantation).
BODY WEIGHT: Yes
- The body weight of each animal was recorded with precision of ±1 g on GD 0, 3, 6, 8, 10, 12, 14, 16, 18 and 20.
FOOD CONSUMPTION: Yes
- Food was measured with precision of ± 1 g on GD 0, 3, 6, 8, 10, 12, 14, 16, 18 and 20. Food consumption was also calculated for each interval, including GD 0-6, GD 6-20 and GD 0-20.
WATER CONSUMPTION: No
SACRIFICE:
- Before expected delivery, on GD 20, Caesarean section was performed on each treated dam. Sodium pentobarbital (Euthanimal 40%, 400 mg/mL sodium pentobarbital solution; Supplier: Alfasan Nederland BV, Batch number: 1609291-03, Expiry date:
31 October 2019) administered by intramuscular injection and followed by exsanguination was used for euthanasia.
POST-MORTEM EXAMINATIONS: Yes
- The dams’ viscera were examined macroscopically for any structural abnormalities or pathological changes. - Ovaries and uterine content:
- The ovaries and uterine content was examined after termination: Yes
Examinations included:
- Gravid uterine weight: Yes
- Cervix weight: Yes
- Number of corpora lutea: Yes
- Number of implantations: Yes
- Number of live foetuses: Yes
- Number of early and late embryonic death: Yes
- Number of foetal death: Yes
- Degree of resorptions: Yes
- Number and percentage of pre- and postimplantation losses: Yes - Fetal examinations:
- - External examinations: Yes (all per litter). Each foetus was weighed individually (accuracy ±0.01 g) and subjected to external examination, plus an additional examination of the great arteries. The gender of foetuses was determined according to the appearance of the anogenital distance.
- Soft tissue examinations: Yes. For the foetuses subjected to visceral examination, the abdominal and thoracic region was opened and the thymus and great arteries were examined by means of a dissecting microscope.
- Skeletal examinations: Yes. For the foetuses subjected to skeletal examination, the abdominal region was opened, and the viscera and skin of foetuses were removed and the cadaver was fixed in alcian-blue - acetic acid – ethanol/isopropanol mixture. After fixation in isopropanol the skeletons were stained by KOH-Alizarin red-S method and examined by means of a dissecting microscope.
- Head examinations: No
- Other: All abnormalities (external, soft tissue and skeletal malformations, and variations) found during the foetal examinations were recorded; photographic records were made additionally. - Statistics:
- In case of the SAS v9.2 software package (within the validated Provantis system) the following decision tree was applied automatically for statistical evaluation of numeric data. The normality and heterogeneity of variance between groups were checked by Shapiro-Wilk and Levene tests using the most appropriate data format (log-transformed when justified). Where both tests showed no significant heterogeneity, an Anova / Ancova (one-way analysis of variance) test was carried out. If the obtained result was positive, Dunnett’s (Multiple Range) test was used to assess the significance of inter-group differences; identifying differences of <0.05 or <0.01 as appropriate. This parametric analysis was the better option when the normality and heterogeneity assumptions implicit in the tests were adequate.
If either of the Shapiro-Wilk or Levene tests showed significance on the data, then a non-parametric analysis was used. A Kruskal-Wallis analysis of variance was used after Rank Transformation. If there was a positive result, the inter-group comparisons were performed using Dunn test; identifying differences of <0.05 or <0.01 as appropriate.
In case of the SPSS PC+4.0 program package, the heterogeneity of variance between groups was checked by Bartlett's test. Where no significant heterogeneity was detected, a one-way analysis of variance (ANOVA) was carried out. If the obtained result was significant, then Duncan's Multiple Range test was used to assess the significance of inter-group differences. Where significant heterogeneity was found, the normal distribution of data was examined by Kolmogorow-Smirnow test. In the case of not normal distribution, the non-parametric method of Kruskal-Wallis One-Way analysis of variance was applied. If a positive result was detected, the inter-group comparisons were performed using Mann-Whitney U-test. The Chi squared test was used for comparing group incidences against the controls. - Indices:
- Percentage pre-implantation loss was calculated as:
[(number of corpora lutea-number of implantations)/number of corpora lutea] x 100
Percentage post-implantation loss was calculated as:
[(number of implantations - number of live fetuses)/number of implantations] x 100
Sex ratio was calculated as:
% male (female) fetuses = (number of male (female) fetuses/total number of fetuses) x 100
External abnormalities/litter: %, group mean (The types and incidences of any abnormality or relevant alterations were individually listed.)
(Number of foetuses with abnormality x100)/ Number of foetuses
Visceral abnormalities/litter: %, group mean (The types and incidences of any abnormality or relevant alterations were individually listed.)
(Number of foetuses with abnormality x100) / Number of foetuses
Skeletal abnormalities/litter: %, group mean (The types and incidences of any abnormality or relevant alterations were individually listed.)
(Number of foetuses with abnormality x100)/ Number of foetuses
Results and discussion
Results: maternal animals
General toxicity (maternal animals)
- Clinical signs:
- effects observed, treatment-related
- Description (incidence and severity):
- Thin fur and/or alopecia on some animals were observed in all groups (Control: 5 out of 25 animals, Low, Mid and High dose groups: 2 out of 24, 25, and 25 animals, respectively). Slightly noisy respiration was observed in 1 animal out of 24 in the Low dose group (66.7 mg/kg bw/day). These changes were most probably incidental, and not considered to be test item related effects.
Piloerection was present in 1 out of 24 animals in the Low dose group (66.7 mg/kg bw/day), and all animals in the Mid and High dose groups (25 out of 25 animals, 200, and 600 mg/kg bw, respectively). Furthermore, hunched back was observed in 14 out of 25 animals in the High dose group (600 mg/kg bw/day). Two High dose animals showed red discharge from the nose, and one of these animals (animal number 4510) had decreased activity from Day 17. Based on the dose dependency and consistency of these effect in the Mid and High dose groups (200 and 600 mg/kg bw/day), they are considered to be test-item related, adverse maternal effects. - Dermal irritation (if dermal study):
- not examined
- Mortality:
- mortality observed, non-treatment-related
- Description (incidence):
- One High dose animal died on GD15 after tonic convulsion of the whole body, following a gavage accident. Due to a technical error (different cage was selected and moved to the necropsy room), one Low dose animal was preterminally euthanized.
- Body weight and weight changes:
- effects observed, treatment-related
- Description (incidence and severity):
- Statistically significant body weight reduction was observed in the High dose group (600 mg/kg bw/day) from GD 12 up to the end of the treatment. These changes resulted in a statistically significant reduction of body weight gain, corrected body weight gain and net body weight gain values during the treatment period (GD 6-20) and the entire study (GD 0-20) when compared to the control values.
No test item related effect on body weight was observed in the Low and the Mid dose groups (66.7, and 200 mg/kg bw/day) when compared to control. Similarly, no statistically significant or biologically relevant differences were seen in the body weight gain or corrected body weight gain or net body weight gain values during the treatment period (GD 6-20) or entire study (GD 0-20) compared to the control value, for these groups - Food consumption and compound intake (if feeding study):
- effects observed, treatment-related
- Description (incidence and severity):
- The mean daily food consumption was statistically significantly lower between GD 6 and 10; and between GD 12 and 14 in the Mid dose group (200 mg/kg), and between GD 6 and 14 in the High dose group (600 mg/kg). Although the food consumption was normalized by the end of the treatment, food consumption for the treatment period and the entire period of the study was statistically significantly lower for these two groups. These lower food intake values were considered to be test item related effects.
- Food efficiency:
- not examined
- Water consumption and compound intake (if drinking water study):
- not examined
- Ophthalmological findings:
- not examined
- Haematological findings:
- not examined
- Clinical biochemistry findings:
- not examined
- Urinalysis findings:
- not examined
- Behaviour (functional findings):
- not examined
- Immunological findings:
- not examined
- Organ weight findings including organ / body weight ratios:
- not examined
- Gross pathological findings:
- effects observed, treatment-related
- Description (incidence and severity):
- Focal or multifocal thickening of the non-glandular mucosal region of the stomach was observed in 1 out of 25 Mid dose (200 mg/kg bw/day) and 12 out of 25 High dose (600 mg/kg bw/day) animals. Furthermore, one High dose animal showed red discolouration of the same region in the stomach. These findings are considered to be test item related, local adverse effects, probably an irritant effect in the stomach.
Correlated to the clinical observations in the in life phase, alopecia or thin fur was observed on some animals in all groups. However, these finding were considered as incidental and not related to the test item administration.
Perforation of the thoracic region of the oesophagus, yellow, dried material on the face of the animal (perioral), and non-collapsed lung with diffuse, dark red discoloration on all lobes were observed in the animal found dead, indicating a gavage accident, and not a test-item related death. - Neuropathological findings:
- not examined
- Histopathological findings: non-neoplastic:
- not examined
- Histopathological findings: neoplastic:
- not examined
- Other effects:
- not examined
- Details on results:
- The maternal findings showed a clear maternal toxicity at the High dose, with clinical signs, signs of stomach irritation, and lower food intake and body weight than controls (Average body weight on GD 20 was approximately 8% below control). In the Mid dose group piloerection was observed in most animals, 1/25 animals had an indication of stomach irritation, the group had a transient lower food intake, but there was no consequence on body weight. It is concluded that there was a slight maternal toxicity at the Mid dose.
Maternal developmental toxicity
- Number of abortions:
- effects observed, treatment-related
- Description (incidence and severity):
- The percentage of the early embryonic loss was significantly higher in the High dose group.
See section 'Any additional information on results' for detailed data tables. - Pre- and post-implantation loss:
- effects observed, treatment-related
- Description (incidence and severity):
- Number of implantations showed a statistically significant decrease in the High dose group, while in the Low and Mid dose groups, the measured values were comparable to the control values.
- preimplantation loss: 9.92%, 13.88%, 15.27% and 17.65% at 0, 66.7, 200, and 600 mg/kg bw/day respectively.
- post-implantation loss: 3.82%, 2.15%, 7.87% and 8.45% at 0, 66.7, 200, and 600 mg/kg bw/day respectively.
See section 'Any additional information on results' for detailed data tables. - Total litter losses by resorption:
- no effects observed
- Description (incidence and severity):
- There were no total litter losses by resorption observed. See Section 'Additional information on results' for more details.
- Early or late resorptions:
- no effects observed
- Description (incidence and severity):
- There were no treatment-related effects on early or late resorptions observed. See Section 'Additional information on results' for more details.
- Dead fetuses:
- no effects observed
- Description (incidence and severity):
- There were no treatment related effects on the number of dead fetuses observed.
See section 'Any additional information on results' for detailed data tables. - Changes in pregnancy duration:
- no effects observed
- Description (incidence and severity):
- There were no total litter losses by resorption observed. See Section 'Additional information on results' for more details.
- Changes in number of pregnant:
- no effects observed
- Description (incidence and severity):
- The number of confirmed pregnant evaluated dams was 23/24 in the Control group, 21/24 in the Low dose group (66.7 mg/kg bw/day), 24/25 in the Mid dose group (200 mg/kg bw/day) and 20/25 in the High dose group (600 mg/kg bw/day).
Originally, mating of 24 animals per groups was planned. However, one extra animal per group was mated for the Mid and High dose groups, to ensure the required number of pregnant, evaluated animals in the study.
See section 'Any additional information on results' for detailed data tables. - Other effects:
- not specified
- Details on maternal toxic effects:
- While other statistically significant differences were found in the number of corpora lutea and total intrauterine mortality in the Mid and High dose groups, these findings were not considered to be the consequence of a test item related, adverse effect.
Although the number of corpora lutea was statistically significantly higher in the Mid dose groups, this increase is considered to be incidental, and the mean number of corpora lutea was comparable with the control in all test item treated groups. The treatment of animals started after the formation of the corpora lutea, so this difference cannot be treatment related.
See section 'Any additional information on results' for detailed data tables.
Effect levels (maternal animals)
- Key result
- Dose descriptor:
- NOAEL
- Effect level:
- 66.7 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Basis for effect level:
- body weight and weight gain
- clinical signs
- food consumption and compound intake
- gross pathology
- Remarks on result:
- other: Based on significant maternal effects at 600 mg/kg and slight, local effects at 200 mg/kg bw/day.
Results (fetuses)
- Fetal body weight changes:
- no effects observed
- Description (incidence and severity):
- All of the external findings were consistent in general nature and incidence with the concurrent study control data / existing historical control data or showed incidental occurrence; therefore, they were considered as incidental findings.
See section 'Any additional information on results' for detailed data tables. - Reduction in number of live offspring:
- effects observed, treatment-related
- Description (incidence and severity):
- The mean number of viable foetuses was significantly lower in the High dose group when compared to the control. The mean number of viable foetuses was comparable with the control mean in the Low and Mid dose groups.
See section 'Any additional information on results' for detailed data tables. - Changes in sex ratio:
- effects observed, non-treatment-related
- Description (incidence and severity):
- There was no statistically significant difference in the sex distribution of foetuses between the control and treatment groups.
See section 'Any additional information on results' for detailed data tables. - Changes in litter size and weights:
- effects observed, non-treatment-related
- Description (incidence and severity):
- The mean foetal weight per litter in the test item did not differ significantly from the control mean value in any treated group.
See section 'Any additional information on results' for detailed data tables. - Changes in postnatal survival:
- not examined
- External malformations:
- effects observed, non-treatment-related
- Description (incidence and severity):
- All of the external findings were consistent in general nature and incidence with the concurrent study control data / existing historical control data or showed incidental occurrence, therefore considered as incidental findings.
See section 'Any additional information on results' for detailed data tables. - Skeletal malformations:
- effects observed, non-treatment-related
- Description (incidence and severity):
- All of the skeletal findings corresponded with the current historical control or the concurrent study control data, or were considered to be incidental findings without dose response.
See section 'Any additional information on results' for detailed data tables. - Visceral malformations:
- effects observed, non-treatment-related
- Description (incidence and severity):
- All of the visceral findings (variations) were consistent in general nature and incidence with the concurrent study control data / existing historical control data or showed incidental occurrence (in the case of convoluted ureter, which was present only in the High dose group, with a greater occurrence than in the historical control); therefore, they were considered as incidental findings.
See section 'Any additional information on results' for detailed data tables. - Other effects:
- not specified
- Details on embryotoxic / teratogenic effects:
- While the mean early embryonic loss values of the test item treated groups were comparable with control, the percentage of the early embryonic loss was significantly higher in the High dose group. No statistically significant difference was found for the Low or Mid dose values when compared to the control.
The late embryonic loss values of the test item treated groups were comparable with control. The number of dead foetuses were 1, 0, 1, and 0 in 1, 0, 1 and 0 litters for the Control, Low, Mid and High dose groups, respectively. There was no statistically significant difference in the postimplantation loss between the test item treated and control groups. Although total intrauterine mortality was significantly higher in the Mid and High dose groups, this statistical significance was considered to be due to the low Postimplantation loss values for the Control group in this particular study, and most probably not a toxicological effect.
There were no test item related effects on external or visceral development of foetuses in the study. In one High dose litter there was a relatively high incidence of retarded ossification at skeletal examination, this litter also had reduced foetal weights; the findings are compatible with the maternal toxicity in this group. There were no other differences observed between the groups at foetal examination.
Foetal malformations observed in the study were all considered to be incidental, they showed no dose dependency, thus not regarded as a test item related effect.
See section 'Any additional information on results' for detailed data tables.
Effect levels (fetuses)
open allclose all
- Key result
- Dose descriptor:
- NOAEL
- Remarks:
- Foetotoxicity
- Effect level:
- 200 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- reduction in number of live offspring
- fetal/pup body weight changes
- skeletal malformations
- Remarks on result:
- other: In the High dose group (600 mg/kg b/day), the incidence of runts was higher and foetal viability was slightly lower than control; also one litter had reduced foetal weight and reduced ossification; these observations were attributed to maternal toxicity.
- Key result
- Dose descriptor:
- NOAEL
- Remarks:
- embryotoxicity
- Effect level:
- >= 600 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- other: Based on the lack of any test-item related intrauterine effect in any treatment group.
- Remarks on result:
- not determinable due to absence of adverse toxic effects
- Key result
- Dose descriptor:
- NOAEL
- Remarks:
- Teratogenicity
- Effect level:
- >= 600 mg/kg bw/day (nominal)
- Based on:
- test mat.
- Sex:
- male/female
- Basis for effect level:
- fetal/pup body weight changes
- skeletal malformations
- other: Based on the lack of any developmental effects in any treatment group.
- Remarks on result:
- not determinable due to absence of adverse toxic effects
Overall developmental toxicity
- Key result
- Developmental effects observed:
- yes
- Lowest effective dose / conc.:
- 600 mg/kg bw/day (nominal)
- Treatment related:
- yes
- Relation to maternal toxicity:
- developmental effects as a secondary non-specific consequence of maternal toxicity effects
- Dose response relationship:
- not specified
- Relevant for humans:
- not specified
Any other information on results incl. tables
Detailed data tables:
Table 1: summary of pregnancy data
Parameters |
Dose (mg/kg bw/day) |
|||
0 |
66.7 |
200 |
600 |
|
Number of mated females |
24 |
24 |
25 |
25 |
Pre-terminal death or euthanasia |
0 |
1 |
0 |
1 |
Number of non-pregnant females |
1 |
2 |
1 |
4 |
Number of females with ≤ 5 implantation sites |
0 |
0 |
0 |
1 |
Number of evaluated females |
23 |
21 |
24 |
20 |
Table 2: Summary of the intraunterine evaluation
Parameters |
Dose (mg/kg bw/day) |
|
|||
0 |
66.7 |
200 |
600 |
|
|
Number of evaluated dams |
23 |
21 |
24 |
20 |
|
Mean number of corpora lutea |
11.74 +/-1.48 |
11.76 +/-1.73 |
12.71* +/-1.27 |
11.45 +/-1.82 |
DN |
Preimplantation loss, mean |
1.22 +/-1.20 |
1.76 +/-2.12 |
1.96 +/-1.27 |
2.05 +/-1.79 |
NS |
Preimplantation loss (%), mean |
9.92 +/-9.58 |
13.88 +/-14.81 |
15.27 +/-9.89 |
17.65 +/-15.96 |
NS |
Mean number of implantations |
10.52 +/-1.38 |
10.00 +/-1.79 |
10.75 +/-1.54 |
9.40* +/-2.21 |
DN |
Early embryonic loss, mean |
0.26 +/-0.69 |
0.05 +/-0.22 |
0.50 +/-1.64 |
0.60 +/-0.75 |
NS |
Early embryonic loss (%), mean |
2.66 +/-7.42 |
0.60 +/-2.73 |
4.21 +/-13.71 |
6.13* +/-7.82 |
U |
Late embryonic loss, mean |
0.09 +/-0.29 |
0.14 +/-0.48 |
0.29 +/-0.91 |
0.20 +/-0.70 |
NS |
Late embryonic loss (%), mean |
0.72 +/-2.40 |
1.56 +/-5.63 |
3.06 +/-9.85 |
2.33 +/-8.52 |
NS |
Dead foetuses, mean |
0.04 +/-0.21 |
0.00 +/-0.00 |
0.04 +/-0.20 |
0.00 +/-0.00 |
NS |
Dead foetuses (%), mean |
0.43 +/-2.09 |
0.00 +/-0.00 |
0.60 +/-2.92 |
0.00 +/-0.00 |
NS |
Postimplantation loss, mean |
0.39 +/-0.78 |
0.19 +/-0.68 |
0.83 +/-1.79 |
0.80 +/-0.89 |
NS |
Postimplantation loss (%), mean |
3.82 +/-8.02 |
2.15 +/-8.27 |
7.87 +/-16.05 |
8.45 +/-10.19 |
NS |
Total intrauterine mortality, mean |
1.61 +/-1.41 |
1.95 +/-2.13 |
2.79* +/-2.11 |
2.85* +/-1.66 |
DN |
Total intrauterine mortality (%), mean |
13.44 +/-11.29 |
15.83 +/-15.93 |
21.89 +/-16.91 |
25.19* +/-14.95 |
DN |
Viable foetuses, mean |
10.13 +/-1.60 |
9.81 +/-1.99 |
9.92 +/-2.30 |
8.60* +/-2.30 |
DN |
Table 2: Summary of the intrauterine evaluation
Notes: Most important parameters are shown in bold.
NS: Statistically not significant when compared to the vehicle control.
DN: *= p<0.05; **= p<0.01; Dunnett two-sided test
U: *= p<0.05; **= p<0.01; Dunn two-sided test
Table 3: Selected body weight parameters
Parameters |
Dose (mg/kg bw/day) |
|
|||
0 |
66.7 |
200 |
600 |
|
|
Number of evaluated dams |
23 |
21 |
24 |
20 |
|
Body weight on GD20 (g) |
317.0 +/-19.3 |
313.3 +/-17.5 |
308.8 +/-22.7 |
291.5** +/-27.6 |
U |
Body weight gain GD6-20 (g) |
79.0 +/-12.0 |
75.8 +/-12.9 |
67.5 +/-14.9 |
49.6** +/-27.9 |
U |
Body weight gain GD0-20 (g) |
98.3 +/-14.3 |
97.3 +/-14.5 |
89.5 +/-15.6 |
71.8** +/-26.5 |
U |
Corrected body weight on GD20 (g) |
258.8 +/-12.9 |
256.5 +/-12.1 |
252.9 +/-16.1 |
244.0* +/-19.8 |
U |
Corrected body weight gain GD0-20 (g) |
40.1 +/-7.8 |
40.5 +/-9.4 |
33.5 +/-11.5 |
24.3** +/-20.0 |
U |
Net body weight gain GD6-20 (g) |
20.8 +/-6.4 |
19.0 +/-5.8 |
11.5 +/-11.7 |
2.1** +/-21.2 |
U |
Gravid Uterus (g) |
58.2 +/-9.5 |
56.8 +/-10.0 |
56.0 +/-10.9 |
47.5** +/-12.8 |
U |
Notes: Body weight data were rounded to one decimal place. Corrected and net weight / weight gains refer to body weight values minus the weight of the gravid uterus.
U: *= p<0.05; **= p<0.01; Dunn two-sided test.
Table 4: Examination of viable foetuses
Parameters |
Dose (mg/kg bw/day) |
|
|||
0 |
66.7 |
200 |
600 |
|
|
Number of examined litters |
23 |
21 |
24 |
20 |
|
Viable foetuses, mean |
10.13 +/-1.60 |
9.81 +/-1.99 |
9.92 +/-2.30 |
8.60* +/-2.30 |
DN |
Male foetuses, mean |
5.30 +/-1.84 |
4.95 +/-1.91 |
4.38 +/-2.20 |
4.50 +/-1.73 |
NS |
Female foetuses, mean |
4.83 +/-1.85 |
4.86 +/-1.59 |
5.54 +/-2.11 |
4.10 +/-2.17 |
NS |
Total number of foetuses |
233 +/-96.3 |
206 +/-98.1 |
238 +/-92.2 |
172* +/-91.5 |
CH2 |
Total number of male foetuses |
122 +/-52.4 |
104 +/-50.5 |
105 +/-44.1 |
90 +/-52.3 |
NS |
Total number of female foetuses |
111 +/-47.6 |
102 +/-49.5 |
133 +/-55.9 |
82 +/-47.7 |
NS |
Sex distribution (% of males / females) |
53 / 47 |
50 / 50 |
43 / 57 |
55 / 45 |
NS |
Mean foetal weight / litter (g) |
3.382 +/-0.217 |
3.397 +/-0.181 |
3.291 +/-0.172 |
3.229 +/-0.466 |
NS |
Number of foetuses with retarded body weight |
6 |
4 |
10 |
25** |
CH2 |
Number of affected litters (with runts) |
5 |
4 |
9 |
7 |
NS |
Notes: Most important parameters are shown in bold.
NS: Statistically not significant when compared to the vehicle control.
DN: *= p<0.05; Dunnett two-sided test
CH2: *= p<0.05; **= p<0.01; Chi Square test
Table 5: Summary table of the external abnormalities
Parameter |
Dose (mg/kg bw/day) |
HC data |
||||||||
0 |
66.7 |
200 |
600 |
|||||||
Total number of examined litters |
23 |
21 |
24 |
20 |
670 |
|||||
Total number of examined foetuses |
233 |
206 |
238 |
172 |
6889 |
|||||
Total number of intact (normal) foetuses |
232 |
203 |
237 |
172 |
-- |
|||||
Total number of foetuses / litters |
1 / 1 |
0 / 0 |
0 / 0 |
0/ 0 |
-- |
|||||
Total number of foetuses / litters |
11 / 0 |
3 / 2 |
1 / 1 |
0 / 0 |
-- |
|||||
External malformations |
||||||||||
Mandible, small |
Litter |
n |
1 |
0 |
0 |
0 |
1 |
|||
% |
4.3 |
0.0 |
0.0 |
0.0 |
0.1 |
|||||
Foetal |
n |
1 |
0 |
0 |
0 |
1 |
||||
% |
0.429 |
0.000 |
0.000 |
0.000 |
0.015 |
|||||
External variations |
||||||||||
Subcutaneous haemorrhage (neck) |
Litter |
n |
0 |
2 |
0 |
0 |
1 |
|||
% |
0.0 |
9.5 |
0.0 |
0.0 |
0.1 |
|||||
Foetal |
n |
0 |
3 |
0 |
0 |
1 |
||||
% |
0.000 |
1.456 |
0.000 |
0.000 |
0.015 |
|||||
Subcutaneous oedema, localized |
Litter |
n |
0 |
0 |
1 |
0 |
-- |
|||
% |
0.0 |
0.0 |
4.2 |
0.0 |
-- |
|||||
Foetal |
n |
0 |
0 |
1 |
0 |
-- |
||||
% |
0.000 |
0.000 |
0.420 |
0.000 |
-- |
|||||
Notes: Numbers represent the number of abnormalities/number of affected litters.
HC: historical control
No statistically significant differences were noted when compared to the control group.
Table 6 Summary table of the visceral abnormalities
Parameter |
Dose (mg/kg bw/day) |
HC data |
|||||
0 |
66.7 |
200 |
600 |
||||
Total number of examined litters |
23 |
21 |
24 |
20 |
670 |
||
Total number of examined foetuses |
116 |
103 |
119 |
86 |
3450 |
||
Total number of intact (normal) foetuses |
114 |
100 |
115 |
79* |
-- |
||
Total number of foetuses / litters |
1 /1 |
0 / 0 |
0 / 0 |
1 / 1 |
-- |
||
Total number of foetuses / litters |
1 / 1 |
3 / 3 |
4 / 3 |
6* / 6 |
-- |
||
Visceral malformations |
|||||||
Situs inversus, total |
Litter |
n |
1 |
0 |
0 |
0 |
4 |
% |
4.3 |
0.0 |
0.0 |
0.0 |
0.6 |
||
Foetal |
n |
1 |
0 |
0 |
0 |
4 |
|
% |
0.862 |
0.000 |
0.000 |
0.000 |
0.116 |
||
Ventricular septum, defect |
Litter |
n |
0 |
0 |
0 |
1 |
1 |
% |
0.0 |
0.0 |
0.0 |
5.0 |
0.1 |
||
Foetal |
n |
0 |
0 |
0 |
1 |
1 |
|
% |
0.000 |
0.000 |
0.000 |
1.163 |
0.029 |
||
Brachiocephalic trunk, short |
Litter |
n |
0 |
0 |
1 |
2 |
45 |
% |
0.0 |
0.0 |
4.2 |
10.0 |
6.7 |
||
Foetal |
n |
0 |
0 |
1 |
2 |
53 |
|
% |
0.000 |
0.000 |
0.840 |
2.326 |
1.536 |
||
Renal papilla, absent, unilateral |
Litter |
n |
0 |
1 |
0 |
0 |
-- |
% |
0.0 |
4.8 |
0.0 |
0.0 |
-- |
||
Foetal |
n |
0 |
1 |
0 |
0 |
-- |
|
% |
0.000 |
0.971 |
0.000 |
0.000 |
-- |
||
Ureter convoluted |
Litter |
n |
0 |
0 |
0 |
3 |
7 |
% |
0.0 |
0.0 |
0.0 |
15.0 |
1.0 |
||
Foetal |
n |
0 |
0 |
0 |
3* |
7 |
|
% |
0.000 |
0.000 |
0.000 |
3.488 |
0.203 |
||
Thymic cord |
Litter |
n |
0 |
1 |
2 |
1 |
69 |
% |
0.0 |
4.8 |
8.3 |
5.0 |
10.3 |
||
Foetal |
n |
0 |
1 |
3 |
1 |
82 |
|
% |
0.000 |
0.971 |
2.521 |
1.163 |
2.377 |
||
Renal papilla, small |
Litter |
n |
1 |
1 |
0 |
0 |
20 |
% |
4.3 |
4.8 |
0.0 |
0.0 |
3.0 |
||
Foetal |
n |
1 |
1 |
0 |
0 |
22 |
|
% |
0.862 |
0.971 |
0.000 |
0.000 |
0.638 |
Notes: Numbers represent the number of abnormalities/number of affected litters.
HC: historical control; n: number, %: of abnormalities
*= p<0.05; Chi Square test
Table 7: Summary table of the skeletal abnormalities
Parameter |
Dose (mg/kg bw/day) |
HC data |
|||||
0 |
66.7 |
200 |
600 |
||||
Total number of examined litters |
23 |
21 |
24 |
20 |
669 |
||
Total number of examined foetuses |
117 |
103 |
119 |
86 |
3435 |
||
Total number of intact (normal) foetuses |
105 |
91 |
107 |
74 |
-- |
||
Total number of foetuses / litters with malformation |
2 / 2 |
4 / 3 |
1 / 1 |
1 / 1 |
-- |
||
Total number of foetuses / litters with variation |
10 / 9 |
8 / 6 |
11 / 8 |
11 / 7 |
-- |
||
Skeletal malformations |
|||||||
Skull: Mandible, short, fused |
Litter |
n |
1 |
0 |
0 |
0 |
1 |
% |
4.3 |
0.0 |
0.0 |
0.0 |
0.1 |
||
Foetal |
n |
1 |
0 |
0 |
0 |
1 |
|
% |
0.855 |
0.000 |
0.000 |
0.000 |
0.029 |
||
Scapula, short |
Litter |
n |
0 |
0 |
1 |
0 |
-- |
% |
0.0 |
0.0 |
4.2 |
0.0 |
-- |
||
Foetal |
n |
0 |
0 |
1 |
0 |
-- |
|
% |
0.000 |
0.000 |
0.840 |
0.000 |
-- |
||
Transverse process fused; Pelvic girdle, malpositioned |
Litter |
n |
1 |
3 |
0 |
1 |
6 |
% |
4.3 |
14.3 |
0.0 |
5.0 |
0.9 |
||
Foetal |
n |
1 |
4 |
0 |
1 |
6 |
|
% |
0.855 |
3.883 |
0.000 |
1.163 |
0.175 |
||
Skeletal variation |
|||||||
Skull: 4 or More Bones, Incomplete Ossification |
Litter |
n |
3 |
2 |
1 |
1 |
123 |
% |
13.0 |
9.5 |
4.2 |
5.0 |
18.4 |
||
Foetal |
n |
4 |
3 |
1 |
1 |
153 |
|
% |
3.419 |
2.913 |
0.840 |
1.163 |
4.454 |
||
Skull: Unossified |
Litter |
n |
1 |
0 |
1 |
1 |
3 |
% |
4.3 |
0.0 |
4.2 |
5.0 |
0.5 |
||
Foetal |
n |
1 |
0 |
1 |
3 |
4 |
|
% |
0.855 |
0.000 |
0.840 |
3.488 |
0.116 |
||
Skull: Hyoid, body, unossified |
Litter |
n |
0 |
0 |
0 |
1 |
-- |
% |
0.0 |
0.0 |
0.0 |
5.0 |
-- |
||
Foetal |
n |
0 |
0 |
0 |
1 |
-- |
|
% |
0.000 |
0.000 |
0.000 |
1.163 |
-- |
||
Skull: Fontanelle Large |
Litter |
n |
0 |
0 |
1 |
1 |
3 |
% |
0.0 |
0.0 |
4.2 |
5.0 |
0.45 |
||
Foetal |
n |
0 |
0 |
1 |
1 |
3 |
|
% |
0.000 |
0.000 |
0.840 |
1.163 |
0.087 |
Sternum: Ossified Sternebra (3 or less) # |
Litter |
n |
1 |
2 |
2 |
3 |
48 |
% |
4.3 |
9.5 |
8.3 |
15.0 |
7.2 |
||
Foetal |
n |
1 |
2 |
3 |
6*CH |
57 |
|
% |
0.855 |
1.942 |
2.521 |
6.977 |
1.659 |
||
Sternum: Misaligned |
Litter |
n |
0 |
0 |
1 |
0 |
7 |
% |
0.0 |
0.0 |
4.2 |
0.0 |
1.046 |
||
Foetal |
n |
0 |
0 |
2 |
0 |
7 |
|
% |
0.000 |
0.000 |
1.681 |
0.000 |
0.204 |
||
Sternum: Sternebra, branched |
Litter |
n |
0 |
0 |
1 |
0 |
-- |
% |
0.0 |
0.0 |
4.2 |
0.0 |
-- |
||
Foetal |
n |
0 |
0 |
1 |
0 |
-- |
|
% |
0.000 |
0.000 |
0.840 |
0.000 |
-- |
||
Sternum: Sternebra, misshapen, split |
Litter |
n |
1 |
0 |
0 |
0 |
-- |
% |
4.3 |
0.0 |
0.0 |
0.0 |
-- |
||
Foetal |
n |
1 |
0 |
0 |
0 |
-- |
|
% |
0.855 |
0.000 |
0.000 |
0.000 |
-- |
||
Ribs: Wavy, marked |
Litter |
n |
1 |
2 |
1 |
2 |
198 |
% |
4.3 |
9.5 |
4.2 |
10.0 |
29.6 |
||
Foetal |
n |
2 |
3 |
2 |
2 |
311 |
|
% |
1.709 |
2.913 |
1.681 |
2.326 |
9.054 |
||
Ribs: Rib or Cartilage Interrupted |
Litter |
n |
1 |
0 |
1 |
0 |
123 |
% |
4.3 |
0.0 |
4.2 |
0.0 |
18.4 |
||
Foetal |
n |
1 |
0 |
2 |
0 |
153 |
|
% |
0.855 |
0.000 |
1.681 |
0.000 |
4.454 |
||
Vertebrae: 3 or More Dumbbell or Asymmetric Ossification |
Litter |
n |
1 |
0 |
0 |
0 |
24 |
% |
4.3 |
0.0 |
0.0 |
0.0 |
3.6 |
||
Foetal |
n |
1 |
0 |
0 |
0 |
24 |
|
% |
0.855 |
0.000 |
0.000 |
0.000 |
0.669 |
||
Vertebrae: Sacral Unossified |
Litter |
n |
0 |
0 |
0 |
1 |
-- |
% |
0.0 |
0.0 |
0.0 |
5.0 |
-- |
||
Foetal |
n |
0 |
0 |
0 |
1 |
-- |
|
% |
0.000 |
0.000 |
0.000 |
1.163 |
-- |
||
Vertebrae: Unossified |
Litter |
n |
0 |
0 |
0 |
1 |
-- |
% |
0.0 |
0.0 |
0.0 |
5.0 |
-- |
||
Foetal |
n |
0 |
0 |
0 |
4*CH |
-- |
|
% |
0.000 |
0.000 |
0.000 |
4.651 |
-- |
||
Vertebrae: Dumbbell Shaped |
Litter |
n |
0 |
1 |
0 |
1 |
-- |
% |
0.0 |
4.8 |
0.0 |
5.0 |
-- |
||
Foetal |
n |
0 |
1 |
0 |
1 |
-- |
|
% |
0.000 |
0.971 |
0.000 |
1.163 |
-- |
Vertebrae: Bipartite Ossification |
Litter |
n |
0 |
0 |
1 |
0 |
-- |
% |
0.0 |
0.0 |
4.2 |
0.0 |
-- |
||
Foetal |
n |
0 |
0 |
1 |
0 |
-- |
|
% |
0.000 |
0.000 |
0.840 |
0.000 |
-- |
||
Limbs (C/T): Ischium, Pubis Unossified |
Litter |
n |
0 |
0 |
0 |
1 |
7 |
% |
0.0 |
0.0 |
0.0 |
5.0 |
1.046 |
||
Foetal |
n |
0 |
0 |
0 |
4*CH |
7 |
|
% |
0.000 |
0.000 |
0.000 |
4.651 |
0.204 |
||
Limbs (C/T): Carpal ≤2.5 |
Litter |
n |
0 |
0 |
0 |
2 |
5 |
% |
0.0 |
0.0 |
0.0 |
10.0 |
0.747 |
||
Foetal |
n |
0 |
0 |
0 |
5 |
5 |
|
% |
0.000 |
0.000 |
0.000 |
5.814 |
0.146 |
||
Limbs (C/T): Tarsal ≤3.5 |
Litter |
n |
0 |
0 |
1 |
3 |
60 |
% |
0.0 |
0.0 |
4.2 |
15.0 |
8.968 |
||
Foetal |
n |
0 |
0 |
1 |
6 |
83 |
|
% |
0.000 |
0.000 |
0.840 |
6.977 |
2.416 |
Notes: Numbers represent the number (n) or ratio (%) of abnormalities.
HC: historical control (data provided where considered useful)
CH: Chi2test
* = p < 0.05
#: Ossified sternebra (3 or less) is recorded in the historical control database
Examination of viable foetuses
The total number of retarded foetuses was significantly higher in the High dose group.
The foetal observations in the High dose group were compatible with maternal toxicity, reduced maternal body weight.
Evaluation of placentas
No abnormalities were observed on the placentas of any animals in the Control, Low (66.7 mg/kg bw/day), Mid (200 mg/kg bw/day) or High (600 mg/kg bw/day) dose groups.
Applicant's summary and conclusion
- Conclusions:
- In conclusion, Naphthenic acid, when administered daily by oral gavage to pregnant Hannover Wistar rats from gestation days GD6 to GD19 at 600 mg/kg bw/day induced maternal toxicity, with clinical signs of piloerection and hunched back, reduced food intake, reduced body weight and body weight gain, and thickening of the non-glandular mucosal region of the stomach. The Mid dose of 200 mg/kg bw/day had lesser signs with no effect on body weight, but there was evidence of a slight maternal toxicity. In the High dose group, the incidence of runts was higher and foetal viability was slightly lower than control; also one litter had reduced foetal weight and reduced ossification; these observations were attributed to maternal toxicity. There were no such effects in the Mid or Low dose groups. There were no malformations or developmental effects attributed to test item at any dose level.
The following no-observed-adverse-effect levels (NOAEL) were derived:
NOAEL(maternal toxicity): 66.7 mg/kg bw/day
Based on significant maternal effects at 600 mg/kg and slight effects at 200 mg/kg bw/day.
NOAEL(embryotoxicity): 600 mg/kg bw/day
Based on the lack of any test-item related intrauterine effect in any treatment group.
NOAEL(foetotoxicity): 200 mg/kg bw/day
Based on the incidence of runts and foetal viability at 600 mg/kg bw/day, attributed to maternal toxicity.
NOAEL(teratogenicity): 600 mg/kg bw/day
Based on the lack of any developmental effects in any treatment group.
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.